Nothing Special   »   [go: up one dir, main page]

EA033168B1 - СТИМУЛЯТОРЫ sGC - Google Patents

СТИМУЛЯТОРЫ sGC

Info

Publication number
EA033168B1
EA033168B1 EA201890641A EA201890641A EA033168B1 EA 033168 B1 EA033168 B1 EA 033168B1 EA 201890641 A EA201890641 A EA 201890641A EA 201890641 A EA201890641 A EA 201890641A EA 033168 B1 EA033168 B1 EA 033168B1
Authority
EA
Eurasian Patent Office
Prior art keywords
sgc
stimulators
pharmaceutically acceptable
acceptable salt
present
Prior art date
Application number
EA201890641A
Other languages
English (en)
Other versions
EA201890641A2 (ru
EA201890641A3 (ru
Inventor
Такаси Накаи
Джоел Мур
Николас Роберт Перл
Раджеш Р. Ийенгар
Ара Мермериан
Г-Йоон Джами Им
Томас Вай-Хо Ли
Коллин Хадсон
Глен Роберт Ренни
Лэй Джиля
Пол Аллен Ренхауэ
Тимоти Клод Барден
Сян Й. Юй
Джеймс Эдвард Шеппек
Картик Айер
Дзоон Дзунг
Джордж Тодд Милн
Кимберли Кафадар Лонг
Марк Г. Карри
Original Assignee
Сайклерион Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сайклерион Терапьютикс, Инк. filed Critical Сайклерион Терапьютикс, Инк.
Publication of EA201890641A2 publication Critical patent/EA201890641A2/ru
Publication of EA201890641A3 publication Critical patent/EA201890641A3/ru
Publication of EA033168B1 publication Critical patent/EA033168B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Изобретение относится к соединению формулы I-531 или его фармацевтически приемлемой солиНастоящее изобретение также раскрывает фармацевтическую композицию в качестве стимулятора растворимой гуанилатциклазы (sGC), содержащую упомянутое выше соединение или его фармацевтически приемлемую соль и один или большее количество инертных наполнителей.
EA201890641A 2013-03-15 2014-03-14 СТИМУЛЯТОРЫ sGC EA033168B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361790637P 2013-03-15 2013-03-15
US201361914915P 2013-12-11 2013-12-11

Publications (3)

Publication Number Publication Date
EA201890641A2 EA201890641A2 (ru) 2018-07-31
EA201890641A3 EA201890641A3 (ru) 2018-11-30
EA033168B1 true EA033168B1 (ru) 2019-09-30

Family

ID=50513493

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201890641A EA033168B1 (ru) 2013-03-15 2014-03-14 СТИМУЛЯТОРЫ sGC
EA201591743A EA031746B1 (ru) 2013-03-15 2014-03-14 СТИМУЛЯТОРЫ sGC

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201591743A EA031746B1 (ru) 2013-03-15 2014-03-14 СТИМУЛЯТОРЫ sGC

Country Status (24)

Country Link
US (8) US9481689B2 (ru)
EP (3) EP3660013B1 (ru)
JP (5) JP2016517432A (ru)
KR (3) KR102218771B1 (ru)
CN (5) CN108912111B (ru)
AU (4) AU2014227862C1 (ru)
BR (1) BR112015023349A2 (ru)
CA (1) CA2907111C (ru)
CY (2) CY1122919T1 (ru)
DK (2) DK3660013T3 (ru)
EA (2) EA033168B1 (ru)
ES (3) ES2966517T3 (ru)
HK (2) HK1213541A1 (ru)
HR (2) HRP20220376T1 (ru)
HU (2) HUE048543T2 (ru)
IL (4) IL285564B2 (ru)
LT (2) LT2970243T (ru)
ME (1) ME03664B (ru)
MX (2) MX361208B (ru)
PL (2) PL2970243T3 (ru)
PT (2) PT3660013T (ru)
RS (2) RS59981B1 (ru)
SI (2) SI3660013T1 (ru)
WO (1) WO2014144100A2 (ru)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2277474A3 (en) 2001-12-20 2013-11-27 TriVascular, Inc. Advanced endovascular graft
EP2654624B1 (en) 2010-12-23 2023-10-04 Twelve, Inc. System for mitral valve repair and replacement
CN107496054B (zh) 2011-06-21 2020-03-03 托尔福公司 人工心脏瓣膜装置及相关系统和方法
US11202704B2 (en) 2011-10-19 2021-12-21 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
CN111000663B (zh) 2011-10-19 2022-04-15 托尔福公司 人工心脏瓣膜装置、人工二尖瓣和相关系统及方法
US9763780B2 (en) 2011-10-19 2017-09-19 Twelve, Inc. Devices, systems and methods for heart valve replacement
EP2750630B1 (en) 2011-10-19 2021-06-30 Twelve, Inc. Device for heart valve replacement
US9039757B2 (en) 2011-10-19 2015-05-26 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US9655722B2 (en) 2011-10-19 2017-05-23 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
EP2797915B1 (en) * 2011-12-27 2016-07-13 Ironwood Pharmaceuticals, Inc. 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure
US9579198B2 (en) 2012-03-01 2017-02-28 Twelve, Inc. Hydraulic delivery systems for prosthetic heart valve devices and associated methods
US9487508B2 (en) 2012-09-19 2016-11-08 Ironwood Pharmaceuticals, Inc. SGC stimulators
EA033168B1 (ru) 2013-03-15 2019-09-30 Сайклерион Терапьютикс, Инк. СТИМУЛЯТОРЫ sGC
WO2014189974A1 (en) 2013-05-20 2014-11-27 Twelve, Inc. Implantable heart valve devices, mitral valve repair devices and associated systems and methods
EP3092231B1 (en) * 2013-12-11 2018-06-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2015106268A1 (en) 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
EP3194386A2 (en) 2014-09-17 2017-07-26 Ironwood Pharmaceuticals, Inc. Sgc stimulators
US20170298055A1 (en) * 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
US20170291889A1 (en) 2014-09-17 2017-10-12 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
EA201790627A1 (ru) * 2014-09-17 2017-09-29 Айронвуд Фармасьютикалз, Инк. СТИМУЛЯТОРЫ рГЦ
RU2020134082A (ru) 2014-10-06 2020-11-27 Вертекс Фармасьютикалз Инкорпорейтед Модуляторы регулятора трансмембранной проводимости при муковисцидозе
CN113750102A (zh) 2015-07-23 2021-12-07 拜耳制药股份公司 可溶性鸟苷酸环化酶的刺激剂和/或活化剂及其用途
CN107920895B (zh) 2015-08-21 2020-06-26 托尔福公司 可植入心脏瓣膜装置、二尖瓣修复装置以及相关系统和方法
CN108883071A (zh) * 2015-11-30 2018-11-23 铁木医药有限公司 包含sGC刺激剂的固体分散体
EP3389655A2 (en) * 2015-12-14 2018-10-24 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION
EP3404021A4 (en) 2016-01-12 2019-09-11 Nippon Chemiphar Co., Ltd. VOLTAGE-RELATED T-TYPE CALCIUM CHANNEL INHIBITOR
CA3012001A1 (en) * 2016-02-01 2017-08-10 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of nonalcoholic steatohepatitis (nash)
ES2946970T3 (es) 2016-03-31 2023-07-28 Vertex Pharma Regulador de conductancia transmembrana de moduladores de fibrosis quística
CN105753783B (zh) * 2016-04-08 2017-12-15 李文淏 一种合成塞来昔布的方法
CN109069272A (zh) 2016-04-29 2018-12-21 美敦力瓦斯科尔勒公司 具有带系绳的锚定件的假体心脏瓣膜设备以及相关联的系统和方法
JP7054395B2 (ja) 2016-07-07 2022-04-13 サイクレリオン・セラピューティクス，インコーポレーテッド 可溶性グアニル酸シクラーゼ刺激剤の新規な調製方法
EP3481820B1 (en) * 2016-07-07 2023-10-18 Cyclerion Therapeutics, Inc. Solid forms of an sgc stimulator
ES2963563T3 (es) 2016-07-07 2024-03-27 Cyclerion Therapeutics Inc Procesos novedosos para preparar estimuladores de guanilato ciclasa soluble
MX2019000103A (es) * 2016-07-07 2019-04-22 Ironwood Pharmaceuticals Inc Profarmacos de fosforo de estimuladores de guanilato ciclasa soluble (sgc).
IL292968A (en) 2016-09-02 2022-07-01 Cyclerion Therapeutics Inc scg motors in converging cycles
EA038096B1 (ru) * 2016-09-23 2021-07-06 Сайклерион Терапьютикс, Инк. ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТА (NASH)
CN109803962B (zh) 2016-09-30 2022-04-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调控蛋白的调节剂、以及药物组合物
CA3039735A1 (en) 2016-10-11 2018-04-19 Bayer Pharma Aktiengesellschaft Combination containing sgc activators and mineralocorticoid receptor antagonists
US10918639B2 (en) 2016-10-11 2021-02-16 Bayer Pharma Aktiengesellschaft Combination containing SGC stimulators and mineralocorticoid receptor antagonists
IL266372B2 (en) 2016-11-08 2023-11-01 Cyclerion Therapeutics Inc Running SGC
HUE052205T2 (hu) 2016-12-09 2021-04-28 Vertex Pharma Cisztás fibrózis transzmembrán vezetõképesség szabályzó modulátora, gyógyszerészeti készítmények, kezelési eljárások és eljárás a modulátor elõállítására
WO2018111795A2 (en) 2016-12-13 2018-06-21 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of esophageal motility disorders
US10702378B2 (en) 2017-04-18 2020-07-07 Twelve, Inc. Prosthetic heart valve device and associated systems and methods
US10433961B2 (en) 2017-04-18 2019-10-08 Twelve, Inc. Delivery systems with tethers for prosthetic heart valve devices and associated methods
US10575950B2 (en) 2017-04-18 2020-03-03 Twelve, Inc. Hydraulic systems for delivering prosthetic heart valve devices and associated methods
US10792151B2 (en) 2017-05-11 2020-10-06 Twelve, Inc. Delivery systems for delivering prosthetic heart valve devices and associated methods
US10646338B2 (en) 2017-06-02 2020-05-12 Twelve, Inc. Delivery systems with telescoping capsules for deploying prosthetic heart valve devices and associated methods
US10709591B2 (en) 2017-06-06 2020-07-14 Twelve, Inc. Crimping device and method for loading stents and prosthetic heart valves
EP3634402A1 (en) 2017-06-08 2020-04-15 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
US10786352B2 (en) 2017-07-06 2020-09-29 Twelve, Inc. Prosthetic heart valve devices and associated systems and methods
US10729541B2 (en) 2017-07-06 2020-08-04 Twelve, Inc. Prosthetic heart valve devices and associated systems and methods
US11517564B2 (en) 2017-07-17 2022-12-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
JP7121794B2 (ja) 2017-08-02 2022-08-18 バーテックス ファーマシューティカルズ インコーポレイテッド ピロリジン化合物を調製するためのプロセス
US11389449B2 (en) 2017-09-14 2022-07-19 Cyclerion Therapeutics, Inc. Treatment of metabolic syndrome with an sGC stimulator
AU2018351533B2 (en) 2017-10-19 2023-02-02 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
MX2020005753A (es) 2017-12-08 2020-08-20 Vertex Pharma Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica.
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
EP3727388A1 (en) * 2017-12-19 2020-10-28 Cyclerion Therapeutics, Inc. Sgc stimulators
CN118221665A (zh) 2018-01-10 2024-06-21 赛克里翁治疗有限公司 用于制备可溶性鸟苷酸环化酶刺激剂的方法及中间物
WO2019161534A1 (en) * 2018-02-22 2019-08-29 Ironwood Pharmaceuticals, Inc. Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators
CN108129387B (zh) * 2018-01-31 2020-05-22 南京药石科技股份有限公司 一种合成2-氮杂二环[4．1．0]庚烷-1-甲酸盐酸盐的制备方法
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CA3098475A1 (en) 2018-04-30 2019-11-07 Bayer Aktiengesellschaft The use of sgc activators and sgc stimulators for the treatment of cognitive impairment
US11508483B2 (en) 2018-05-30 2022-11-22 Adverio Pharma Gmbh Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group
BR112021000358A2 (pt) 2018-07-11 2021-04-06 Cyclerion Therapeutics, Inc. Uso de estimulantes de sgc para o tratamento de distúrbios mitocondriais
KR20210102892A (ko) * 2018-12-05 2021-08-20 유로반트 사이언시즈 게엠베하 과민성 방광 증상의 치료를 위한 비베그론
EP3893755A4 (en) * 2018-12-13 2023-01-25 NXT Biomedical, LLC METHODS AND DEVICES FOR BLOOD OXYGENATION TREATMENT
EP3911675A1 (en) 2019-01-17 2021-11-24 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
BR102019016950A2 (pt) * 2019-08-15 2021-02-23 Inst De Pesquisa Ensino Ciencia E Tecnologia Aplicada Inst Galzu forma de dosagem intrauretral de medicamento; e dispositivo
US20230087609A1 (en) 2020-02-21 2023-03-23 Universiteit Maastricht USE OF A SOLUBLE GUANYLATE CYCLASE (sGC) STIMULATOR OR OF A COMBINATION OF A sGC STIMULATOR AND AN sGC ACTIVATOR FOR CONDITIONS WHEREIN THE HEME GROUP OF sGC IS OXIDIZED OR WHEREIN sGC IS DEFICIENT IN HEME
US20230083417A1 (en) 2020-02-26 2023-03-16 Universiteit Maastricht Therapeutic combination for the treatment of brain ischemia and said therapeutic combination for use in the treatment of brain ischemia
CN111440315B (zh) * 2020-04-28 2021-07-02 中国科学院长春应用化学研究所 一种自修复热塑性聚脲弹性体及其制备方法
CN112142716B (zh) * 2020-10-29 2021-08-31 山东新时代药业有限公司 一种5元杂芳基取代的吡嗪衍生物及其应用
CN112569179B (zh) * 2020-12-25 2022-12-27 上海交通大学医学院附属第九人民医院 一种可注射水凝胶体系及其制备方法
CN114957087A (zh) * 2022-04-13 2022-08-30 湖南复瑞生物医药技术有限责任公司 一种帕罗韦德中间体制备方法
CN115932092A (zh) * 2022-12-02 2023-04-07 中国科学院昆明植物研究所 玛咖产品中添加有pde-5抑制剂的检测方法与应用
CN117582909B (zh) * 2024-01-19 2024-04-02 天津凯莱英医药科技发展有限公司 一种连续生产5-单硝酸异山梨酯的系统和方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012003405A1 (en) * 2010-06-30 2012-01-05 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2012064559A1 (en) * 2010-11-09 2012-05-18 Ironwood Pharmaceuticals, Inc. Sgc stimulators

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4203440A (en) 1978-10-23 1980-05-20 Alza Corporation Device having variable volume chamber for dispensing useful agent
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
EP0192963B1 (de) 1985-02-27 1988-07-20 Werkzeugmaschinenfabrik Oerlikon-Bührle AG Schwingungsmesseinrichtung für ein Spiralkegelradgetriebe auf einer Zahnradprüfmaschine
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5721365A (en) 1989-09-15 1998-02-24 Us Health N-substituted piperazine NONOates
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5324280A (en) 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5155137A (en) 1990-09-20 1992-10-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Complexes of nitric oxide with polyamines
EP0605622B1 (en) 1991-09-24 1997-11-12 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs
US5571897A (en) 1991-12-05 1996-11-05 Wallac Oy Luminescent lanthanide chelates
US5814666A (en) 1992-04-13 1998-09-29 The United States As Represented By The Department Of Health And Human Services Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents
US5405919A (en) 1992-08-24 1995-04-11 The United States Of America As Represented By The Secretary Of Health And Human Services Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders
US5910316A (en) 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
US5691423A (en) 1992-08-24 1997-11-25 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-bound nitric oxide-nucleophile adducts
US5632981A (en) 1992-08-24 1997-05-27 The United States Of America As Represented By The Department Of Health And Human Services Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
WO1995010267A1 (en) 1993-10-08 1995-04-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of nitric oxide-releasing compounds as hypoxic cell radiation sensitizers
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
US5700830A (en) 1994-11-22 1997-12-23 The United States Of America As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents for reducing metastasis risk
US5470862A (en) * 1995-02-03 1995-11-28 Ohmeda Pharmaceutical Products Division Inc. Substituted pyrazolyl compounds and methods employing such compounds
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
ES2270438T3 (es) 1995-06-21 2007-04-01 SHIONOGI &amp; CO., LTD. Derivados amino biciclicos y agonista de pgd2 que contienen los mismos.
US5714511A (en) 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
WO1998025915A1 (fr) 1996-12-12 1998-06-18 Shionogi & Co., Ltd. Derives d'amide d'acide benzenecarboxylique condenses heterocycliques et antagonistes pgd2 renfermant ces derives
TR199901280T2 (xx) 1996-12-13 1999-10-21 Shionogi & Co., Ltd. Benzotiofenekarboksamid t�revleri ve bunlar� i�eren PGD2 antagonistleri.
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE69928260T2 (de) 1998-07-08 2006-07-20 Sanofi-Aventis Deutschland Gmbh Schwefel-substituierte sulfonylaminocarbonsäure n-arylamide, ihre herstellung, ihre anwendung und diese enthaltende pharmazeutische zusammensetzungen
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
NZ512410A (en) 1998-12-17 2003-02-28 Alza Corp Controlled release liquid filled gelatin capsules comprising barrier, expandable and superpermeable layers and an orifice
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US20010051624A1 (en) 2000-04-12 2001-12-13 Jones Thomas R. Method and compositions for the treatment of allergic conditions using PGD2 receptor antagonists
JP2003530426A (ja) 2000-04-12 2003-10-14 メルク フロスト カナダ アンド カンパニー Ｐｇｄ２受容体拮抗薬を用いるアレルギー状態の治療のための方法および組成物
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
AR035431A1 (es) 2001-02-13 2004-05-26 Aventis Pharma Gmbh 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas, un metodo para su sintesis, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos
PE20020856A1 (es) 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas
TWI241190B (en) 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
US6511911B1 (en) 2001-04-03 2003-01-28 Advanced Micro Devices, Inc. Metal gate stack with etch stop layer
KR20040044856A (ko) 2001-09-07 2004-05-31 오노 야꾸힝 고교 가부시키가이샤 인돌 유도체 화합물
EP1424325A4 (en) 2001-09-07 2005-12-21 Ono Pharmaceutical Co INDOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE AGENT
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
AU2003231513A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Pgd2 receptor antagonist
AU2003231509A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
DE10244810A1 (de) * 2002-09-26 2004-04-08 Bayer Ag Neue Morpholin-überbrückte Indazolderivate
PL376156A1 (en) 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
WO2004058164A2 (en) 2002-12-20 2004-07-15 Tularik, Inc. Asthma and allergic inflammation modulators
CN100439371C (zh) * 2003-04-29 2008-12-03 辉瑞大药厂 可用于治疗高血压的5,7-二氨基吡唑并[4,3-d]嘧啶
EP1479679A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Triazole-derivatives as factor Xa inhibitors
MXPA06001506A (es) 2003-08-04 2006-05-15 Pfizer Prod Inc Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductasa.
US8309608B2 (en) 2003-11-06 2012-11-13 Sanofi-Aventis Deutschland Gmbh Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases
WO2008124505A2 (en) 2007-04-05 2008-10-16 Ironwood Pharmaceuticals,Inc. Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
CA2698332C (en) * 2007-09-06 2012-08-21 Merck Sharp & Dohme Corp. Pyrazole derivatives as soluble guanylate cyclase activators
WO2009094242A1 (en) 2008-01-24 2009-07-30 Merck & Co., Inc. Angiotensin ii receptor antagonists
EP2296661A1 (en) * 2008-05-10 2011-03-23 Bayer Schering Pharma Aktiengesellschaft Sgc stimulators, sgc activators and combinations thereof for the treatment of hearing impairment
AU2009322836B2 (en) 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
RU2011138970A (ru) 2009-02-26 2013-04-10 Мерк Шарп Энд Домэ Корп. Активаторы растворимой гуанилатциклазы
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
EP2549875B1 (en) 2010-03-25 2015-05-13 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
CN102859483B (zh) 2010-04-27 2016-10-19 日本电气株式会社 信息处理终端及其控制方法
AU2011258436B2 (en) 2010-05-27 2014-06-12 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US8895583B2 (en) 2010-10-28 2014-11-25 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP2702055A1 (en) * 2011-04-11 2014-03-05 Nerviano Medical Sciences S.r.l. Pyrazolyl-pyrimidine derivatives as kinase inhibitors
WO2013092512A1 (en) 2011-12-21 2013-06-27 Bayer Intellectual Property Gmbh Substituted benzylpyrazoles
EP2797915B1 (en) 2011-12-27 2016-07-13 Ironwood Pharmaceuticals, Inc. 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure
DE102012200352A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
US9487508B2 (en) 2012-09-19 2016-11-08 Ironwood Pharmaceuticals, Inc. SGC stimulators
EA033168B1 (ru) 2013-03-15 2019-09-30 Сайклерион Терапьютикс, Инк. СТИМУЛЯТОРЫ sGC
EP3092231B1 (en) 2013-12-11 2018-06-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2015106268A1 (en) 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012003405A1 (en) * 2010-06-30 2012-01-05 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2012064559A1 (en) * 2010-11-09 2012-05-18 Ironwood Pharmaceuticals, Inc. Sgc stimulators

Also Published As

Publication number Publication date
CY1125178T1 (el) 2024-12-13
CN105408328A (zh) 2016-03-16
CN108912111A (zh) 2018-11-30
PL3660013T3 (pl) 2022-05-02
EP3660013A1 (en) 2020-06-03
MX361208B (es) 2018-11-30
US10183021B2 (en) 2019-01-22
PL2970243T3 (pl) 2020-06-01
CN110016020B (zh) 2022-07-26
KR102218771B1 (ko) 2021-02-19
IL285564B1 (en) 2024-02-01
JP2017178946A (ja) 2017-10-05
JP2019034952A (ja) 2019-03-07
AU2019203606B9 (en) 2021-04-01
US20160347738A1 (en) 2016-12-01
AU2014227862C1 (en) 2019-05-30
RS59981B1 (sr) 2020-03-31
EP2970243B1 (en) 2019-11-27
SI3660013T1 (sl) 2022-05-31
US20200316065A1 (en) 2020-10-08
SI2970243T1 (sl) 2020-04-30
JP6709000B2 (ja) 2020-06-10
ES2774295T3 (es) 2020-07-20
JP2016517432A (ja) 2016-06-16
JP7072602B2 (ja) 2022-05-20
CN105408328B (zh) 2018-11-16
HK1213541A1 (zh) 2016-07-08
CN109369635A (zh) 2019-02-22
PT3660013T (pt) 2022-04-12
HRP20220376T1 (hr) 2022-07-22
ME03664B (me) 2020-10-20
CA2907111C (en) 2023-10-24
EA201591743A1 (ru) 2016-02-29
AU2023202058A1 (en) 2023-05-04
LT2970243T (lt) 2020-03-10
AU2019203606B2 (en) 2021-03-25
PT2970243T (pt) 2020-03-05
US20230106002A1 (en) 2023-04-06
US10639308B2 (en) 2020-05-05
US10517874B2 (en) 2019-12-31
DK2970243T3 (da) 2020-03-02
EA201591743A8 (ru) 2017-12-29
ES2911276T3 (es) 2022-05-18
AU2019203606A1 (en) 2019-06-13
CN109384778A (zh) 2019-02-26
KR102502937B1 (ko) 2023-02-23
IL285564A (en) 2021-09-30
HRP20200276T1 (hr) 2020-05-29
CN109384778B (zh) 2022-12-13
HUE048543T2 (hu) 2020-07-28
HUE059178T2 (hu) 2022-10-28
EA031746B1 (ru) 2019-02-28
JP6267384B2 (ja) 2018-01-24
WO2014144100A3 (en) 2014-11-06
AU2014227862A1 (en) 2015-11-12
WO2014144100A2 (en) 2014-09-18
CA2907111A1 (en) 2014-09-18
US20160375022A1 (en) 2016-12-29
JP2020143092A (ja) 2020-09-10
ES2966517T3 (es) 2024-04-22
EP3998260C0 (en) 2023-11-01
JP6267385B2 (ja) 2018-01-24
LT3660013T (lt) 2022-04-11
US20190167679A1 (en) 2019-06-06
EP3660013B1 (en) 2022-01-19
MX2021008281A (es) 2022-06-14
KR20210020181A (ko) 2021-02-23
KR20220025191A (ko) 2022-03-03
US11207323B2 (en) 2021-12-28
IL270646B (en) 2021-01-31
BR112015023349A2 (pt) 2017-07-18
US9586937B2 (en) 2017-03-07
EP2970243A2 (en) 2016-01-20
IL241641B (en) 2019-11-28
IL285564B2 (en) 2024-06-01
EP3998260A1 (en) 2022-05-18
US20160031903A1 (en) 2016-02-04
CN109369635B (zh) 2023-06-30
US20170137439A1 (en) 2017-05-18
AU2023202058A2 (en) 2023-05-25
EP3998260B1 (en) 2023-11-01
RS63108B1 (sr) 2022-04-29
AU2021204292B2 (en) 2023-01-05
US20170136019A1 (en) 2017-05-18
CN108912111B (zh) 2021-09-14
CY1122919T1 (el) 2021-10-29
DK3660013T3 (da) 2022-03-28
KR20150129002A (ko) 2015-11-18
AU2021204292A1 (en) 2021-07-22
CN110016020A (zh) 2019-07-16
EA201890641A2 (ru) 2018-07-31
MX2015012473A (es) 2016-04-19
AU2014227862B2 (en) 2019-02-28
JP2017160225A (ja) 2017-09-14
HK1221723A1 (zh) 2017-06-09
IL279695A (en) 2021-01-31
EA201890641A3 (ru) 2018-11-30
KR102362835B1 (ko) 2022-02-14
IL279695B (en) 2021-08-31
US9481689B2 (en) 2016-11-01

Similar Documents

Publication Publication Date Title
EA033168B1 (ru) СТИМУЛЯТОРЫ sGC
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
PH12016500467A1 (en) Aminoheteroarlyl benzamides as kinase inhibitors
PH12019500480A1 (en) Pyridine compound
PH12015501996B1 (en) Heterocyclic compounds and uses thereof
PH12016502539A1 (en) Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
MX2016007522A (es) Estimuladores de guanilato ciclasa soluble (sgc).
MX2020007023A (es) Analogos detiadiazol y metodos para el tratamiento de afecciones relacionadas con la deficiencia del gen de supervivencia de las neuronas motoras (smn).
MX2013011589A (es) Metodos y composiciones para tratar enfermedad de parkinson.
MX2015011913A (es) Moduladores de acido oxabiciclo[2.2.2] gpr120.
UA115357C2 (uk) Похідні піридин-4-ілу
PH12018500378B1 (en) Novel annelated phenoxyacetamides
PH12016502246A1 (en) Carboxamide derivatives
MX2016004963A (es) Sal y formas cristalinas de inhibidores de quinasa tipo polo-4.
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
PH12020550763A1 (en) Pyridinone derivatives and their use as selective alk-2 inhibitors
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
WO2015002755A3 (en) Compounds for the treatment of malaria
MX2015007309A (es) Derivado de hidantoina.
SG11201803867TA (en) Sodium channel blocker
WO2015102017A8 (en) Processes for the preparation of lorcaserin
MX2015017124A (es) Combinacion de ro5503781, capecitabina y oxaliplatino para la terapia para el cancer.
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
TN2015000058A1 (en) Salts of benzothiazolone compound as beta-2-adrenoceptor agonist